NAMPT抑制剂(CB30865) | 206275-15-2

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: NAMPT抑制剂(CB30865)
• 英文名称: CB 30865
• 英文别名: 4-[(7-bromo-2-methyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-N-(pyridin-3-ylmethyl)benzamide；4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-N-(pyridin-3-ylmethyl)benzamide
• CAS: 206275-15-2
• 化学式: C₂₆H₂₂BrN₅O₂
• 分子量: 516.397
• InChiKey: SHNBLWMBWXIKMR-UHFFFAOYSA-N

物化性质

• 密度：
  1.38±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：33.33 mg/mL（64.54 mM；需要超声波）H2O：< 0.1 mg/mL（不溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性

CB30865 (ZM 242421) 是一种烟酰胺磷酸核糖转移酶（Nampt）抑制剂，具有很强的细胞毒性。在体外，CB30865 能有效抑制多种人类肿瘤细胞系（IC50 值在 1-10 nM 范围内）。

体外研究

CB30865 的细胞毒性是由于通过 Nampt 抑制导致 NAD 合成减少。

文献信息

• [EN] ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE DIHYDROQUINAZOLINE ANTICANCEREUX
  申请人：CANCER RES CAMPAIGN TECH

  公开号：WO2000050417A1

  公开（公告）日：2000-08-31

  A dihydroquinazoline derivative of formula (I), or a pharmaceutically acceptable salt thereof, wherein: either R1 and R1' together form an oxo group and R2 is hydrogen, C1-C4 alkyl, -(C1-C4 alkyl)-COB, -(C1-C4 alkyl)-CO-(C1-C4 alkyl)-B, -(C1-C4 alkyl)-CO2-(C1-C4 alkyl)-B, -(C1-C4 alkyl)-CO2-(C2-C4 alkenyl)-B or -(C1-C4 alkyl)-CONH-(C1-C4 alkyl)-B wherein B is -CO2H, hydroxy, C1-C4 alkoxy, amino, (C1-C4 alkyl)amino, di(C1-C4 alkyl)amino or a 5- or 6-membered heterocyclic group, or R1' and R2 together form a bond and R1 is -S-(C1-C4 alkyl), -NHR' or -NHCOR' wherein R' is aryl or C1-C4 alkyl; R3 is -(CH2)p-A wherein p is from 1 to 4 and A is a 5- or 6-membered N-containing heterocyclic ring attached via the N atom or A is -NA'A' wherein A' and A' are the same or different and are each a C1-C4 alkyl group; either R4 is hydrogen, oxo or C1-C4 alkyl and R5 is hydrogen, C1-C4 alkyl or halogen, or R4 and R5, together with the carbon atoms to which they are attached, form a 5- or 6-membered carbocyclic ring; X1 is -O-, -S- or -NR'- wherein R' is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl; Y is a divalent aryl or heteroaryl group; R6 is hydrogen, oxo or C1-C4 alkyl; X2 is -O-, -S- or -NR'- wherein R' is as defined above; m is from 1 to 4; and R7 is pyridyl, pyrimidyl, imidazolyl, triazolyl, -(C1-C4 alkyl)-imidazolyl, or -(C1-C4 alkyl)-triazolyl.

  公式（I）的二氢喹唑啉衍生物，或其药学上可接受的盐，其中：R1和R1'要么一起形成一个氧代基，且R2为氢、C1-C4烷基、-(C1-C4烷基)-COB、-(C1-C4烷基)-CO-(C1-C4烷基)-B、-(C1-C4烷基)-CO2-(C1-C4烷基)-B、-(C1-C4烷基)-CO2-(C2-C4烯基)-B或-(C1-C4烷基)-CONH-(C1-C4烷基)-B，其中B为-CO2H、羟基、C1-C4烷氧基、氨基、(C1-C4烷基)氨基、二(C1-C4烷基)氨基或5-或6-成员杂环基；或者R1'和R2一起形成一个键，且R1为-S-(C1-C4烷基)、-NHR'或-NHCOR'，其中R'为芳基或C1-C4烷基；R3为-(CH2)p-A，其中p为1至4，A为通过N原子连接的5-或6-成员含N杂环环或A为-NA'A'，其中A'和A'相同或不同，且均为C1-C4烷基；要么R4为氢、氧代基或C1-C4烷基，且R5为氢、C1-C4烷基或卤素，或者R4和R5与它们所连接的碳原子一起形成一个5-或6-成员的碳环；X1为-O-、-S-或-NR'-，其中R'为氢、C1-C4烷基、C2-C4烯基或C2-C4炔基；Y为二价芳基或杂芳基基团；R6为氢、氧代基或C1-C4烷基；X2为-O-、-S-或-NR'-，其中R'如上所定义；m为1至4；R7为吡啶基、嘧啶基、咪唑基、三唑基、-(C1-C4烷基)-咪唑基或-(C1-C4烷基)-三唑基。
• ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：EP1155012B1

  公开（公告）日：2004-04-14
• COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME
  申请人：Hurt Clarence

  公开号：US20210324031A1

  公开（公告）日：2021-10-21

  Novel leptin and leptin-fusion protein-small molecule drug conjugates are disclosed, where conjugation takes place through the use of cleavable and non-cleavable linkers. The small molecules chemically linked to the protein carrier are imported into the specific leptin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug then act to modify leptin receptor-triggered biochemical pathways that are altered in conditions of leptin-resistance. Drug will correct altered pathway allowing resensitization of receptor signaling. This can greatly aid in the resolution of pathologies either initiated at the onset of leptin resistance or exacerbated by it.
• INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS
  申请人：Disarm Therapeutics, Inc.

  公开号：US20220008405A1

  公开（公告）日：2022-01-13

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
• US6699861B1
  申请人：——

  公开号：US6699861B1

  公开（公告）日：2004-03-02